NCT05115006已完成不适用
Adjuvant Melanoma Stakeholder Treatment Preference Study
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 294 人开始时间: 2021年1月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 294
- 试验地点
- 1
- 主要终点
- Preference weights or utilities (a measure of relative preference; on a continuous variable scale) for each treatment attribute level based on responses to the Discrete Choice Experiment (DCE) choice tasks
研究概览
简要总结
The purpose of this study is to understand the trade-offs that participants with surgically treated melanoma would be willing to make among key features and outcomes of adjuvant anti-cancer treatments or no adjuvant treatment / observation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Self-reported medical diagnosis of stage II or stage III melanoma
- •Have been resected (had surgery) for their melanoma within 12 months prior to study participation
排除标准
- •Self-reported stage IIa
- •Self-reported recurrence of melanoma after surgery
- •Other protocol-defined inclusion/exclusion criteria apply
结局指标
主要结局
Preference weights or utilities (a measure of relative preference; on a continuous variable scale) for each treatment attribute level based on responses to the Discrete Choice Experiment (DCE) choice tasks
时间窗: At Baseline
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been RemovedMelanomaNCT03771859Bristol-Myers Squibb152
已完成
不适用
A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT05250817Bristol-Myers Squibb501
招募中
不适用
Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected MelanomaMelanomaNCT05527795Hospices Civils de Lyon1,000
终止
3 期
Stage IV Surgery Versus Best Medical TherapyStage IV Resectable MelanomaNCT01013623Saint John's Cancer Institute12
已完成
不适用
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant OthersPapillary MicrocarcinomaThyroid CancerNCT01392222Memorial Sloan Kettering Cancer Center21